Document is current
Any future updates will be listed below
-
Authors
Sun, Fengze
Liu, Hongquan
Zhang, Dongxu
Ding, Guixin
Chi, Youwei
Wang, Jipeng
Zou, Qingsong
Li, Yongwei
Wu, Jitao
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82270722)
National Natural Science Foundation of China (82370690)
Natural Science Foundation of Shandong Province of China (ZR2023MH241)
Taishan Scholars Program of Shandong Province (tsqn201909199)
Science and Technology Innovation and Development Plan of Yantai (2022YD024)
- License Information
-
More Information
Article History
Received: 21 October 2025
Accepted: 5 February 2026
First Online: 14 February 2026
Declarations
:
: The hiPSC were purchased from iCell Bioscience Inc, which was introduced from ATCC (ATCC number: ACS-1011TM). And the HUVEC was also purchased from iCell Bioscience Inc, which complied with the ethical approval from tissue donation to cell line establishment. The Ethics Committee of the Yantai Yuhuangding Hospital approved the present study of research (The research on hiPSCs-Exo promoting angiogenesis and urethral injury repair, Date: 05/26/2025, Approval No.2025 − 565). All Institutional and National Guidelines for the care and use of animals were followed.
: Not applicable.
: The authors declare no competing interests.
